MedTrace Logo

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

NCT06290388 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-12-04

No results posted yet for this study

Summary

This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.

Conditions

Interventions

DRUG

23ME-01473

23Me-01473 given by intravenous infusion

Sponsors & Collaborators

  • 23andMe, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Low, M.D,Ph.D · 23andMe, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-07
Primary Completion
2024-11-10
Completion
2024-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06290388 on ClinicalTrials.gov